Charles Harper
Obstetrics · Greensboro, NCNPI 1689663999
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 36.0% of the total. Reporting peaked in 2021 at $562 and has fallen 71.5% since, to $160 in 2025.
Across 115 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$670
- Avion Pharmaceuticals$288
- Exeltis, USA Inc.$172
- Organon$98
- Shield Therapeutics Inc$92
- Lupin Inc.$62
- plus $480 from 17 others
Across 300 payments — averaging $1164.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seqirus USA Inc$328K
- AstraZeneca$21K
What the payments were for
- Food & beverage$1,860100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $670 |
| Avion Pharmaceuticals | 25 | $288 |
| Exeltis, USA Inc. | 11 | $172 |
| Organon | 6 | $98 |
| Shield Therapeutics Inc | 6 | $92 |
| Lupin Inc. | 5 | $62 |
| Evofem Biosciences, Inc. | 3 | $60 |
| Merck | 4 | $56 |
| Bayer | 3 | $46 |
| Mylan Pharmaceuticals Inc. | 3 | $42 |
| Mayne Pharma Commercial LLC | 2 | $39 |
| Novo Nordisk | 2 | $34 |
| Dexcom, Inc. | 1 | $28 |
| Biogen | 1 | $27 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Coopersurgical, Inc. | 1 | $21 |
| Therapeuticsmd, Inc. | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Mission Pharmacal Company | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Scynexis, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$1,860 in reported general payments places this provider in the 75th percentile of 33 obstetrics providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Climara ProEstradiol/Levonorgestrel | 22 | $5,688 |
| Tinidazole | 17 | $1,038 |
| Estradiol (Once Weekly)Estradiol | 11 | $495 |
| Metronidazole | 13 | $242 |
| Fluconazole | 32 | $123 |
| Ibuprofen | 11 | $81 |
| Levocetirizine Dihydrochloride | 13 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerClimara Pro | $46 | $5,68822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 33 obstetrics providers in North Carolina.
Other obstetrics in Greensboro
- Kelly FoglemanGreensboro$8K
- Elizabeth LaneGreensboro$2K
- Samantha ShawJacksonville$4K
- Peter McIlveenElkin$3K
- Bertie GengChapel Hill$3K
- John YoonRaleigh$2K
- Camaryn Chrisman RobbinsRaleigh$2K
- Netasha McLawhornRaleigh$2K
- Brian BassRaleigh$2K
- Kenneth JacksonArden$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.